HRP20181082T1 - Derivati piridazina za uporabu za prevenciju ili liječenje ataksičnog poremećaja - Google Patents

Derivati piridazina za uporabu za prevenciju ili liječenje ataksičnog poremećaja Download PDF

Info

Publication number
HRP20181082T1
HRP20181082T1 HRP20181082TT HRP20181082T HRP20181082T1 HR P20181082 T1 HRP20181082 T1 HR P20181082T1 HR P20181082T T HRP20181082T T HR P20181082TT HR P20181082 T HRP20181082 T HR P20181082T HR P20181082 T1 HRP20181082 T1 HR P20181082T1
Authority
HR
Croatia
Prior art keywords
hydroxypyridazin
ethyl
hydroxy
trifluoromethyl
pyridazin
Prior art date
Application number
HRP20181082TT
Other languages
English (en)
Croatian (hr)
Inventor
Sarah Almond
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50554599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20181082(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of HRP20181082T1 publication Critical patent/HRP20181082T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20181082TT 2014-03-06 2015-03-06 Derivati piridazina za uporabu za prevenciju ili liječenje ataksičnog poremećaja HRP20181082T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1403944.0A GB201403944D0 (en) 2014-03-06 2014-03-06 New use
PCT/GB2015/050654 WO2015132608A1 (en) 2014-03-06 2015-03-06 Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
EP15709324.6A EP3113778B1 (en) 2014-03-06 2015-03-06 Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder

Publications (1)

Publication Number Publication Date
HRP20181082T1 true HRP20181082T1 (hr) 2018-09-07

Family

ID=50554599

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20181082TT HRP20181082T1 (hr) 2014-03-06 2015-03-06 Derivati piridazina za uporabu za prevenciju ili liječenje ataksičnog poremećaja

Country Status (32)

Country Link
US (1) US20170014407A1 (cg-RX-API-DMAC7.html)
EP (1) EP3113778B1 (cg-RX-API-DMAC7.html)
JP (1) JP6510549B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160126081A (cg-RX-API-DMAC7.html)
CN (1) CN106102743A (cg-RX-API-DMAC7.html)
AU (1) AU2015225954B2 (cg-RX-API-DMAC7.html)
CA (1) CA2940342A1 (cg-RX-API-DMAC7.html)
CL (1) CL2016002151A1 (cg-RX-API-DMAC7.html)
CY (1) CY1120573T1 (cg-RX-API-DMAC7.html)
DK (1) DK3113778T3 (cg-RX-API-DMAC7.html)
EA (1) EA036438B1 (cg-RX-API-DMAC7.html)
ES (1) ES2676905T3 (cg-RX-API-DMAC7.html)
GB (1) GB201403944D0 (cg-RX-API-DMAC7.html)
GE (1) GEP20196984B (cg-RX-API-DMAC7.html)
HR (1) HRP20181082T1 (cg-RX-API-DMAC7.html)
IL (1) IL247435A0 (cg-RX-API-DMAC7.html)
LT (1) LT3113778T (cg-RX-API-DMAC7.html)
MA (1) MA39315A1 (cg-RX-API-DMAC7.html)
MX (1) MX2016010524A (cg-RX-API-DMAC7.html)
MY (1) MY202127A (cg-RX-API-DMAC7.html)
PH (1) PH12016501751A1 (cg-RX-API-DMAC7.html)
PL (1) PL3113778T3 (cg-RX-API-DMAC7.html)
PT (1) PT3113778T (cg-RX-API-DMAC7.html)
RS (1) RS57594B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201607106YA (cg-RX-API-DMAC7.html)
SI (1) SI3113778T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800367T1 (cg-RX-API-DMAC7.html)
TR (1) TR201809537T4 (cg-RX-API-DMAC7.html)
TW (1) TW201534591A (cg-RX-API-DMAC7.html)
UA (1) UA123352C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015132608A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201604611B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
LT3137456T (lt) 2014-04-29 2021-08-25 Fmc Corporation Piridazinono herbicidai
TWI785022B (zh) 2017-03-28 2022-12-01 美商富曼西公司 新穎噠嗪酮類除草劑
US11213030B2 (en) 2017-06-30 2022-01-04 Fmc Corporation 4-(3,4-dihydronaphth-1-yl or 2H-chromen-4-yl)-5-hydroxy-2H-pyradizin-3-ones as herbicides
CN112569217B (zh) * 2019-09-30 2022-04-22 厦门大学 戊酸衍生物在治疗遗传性小脑共济失调中的应用
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
AU2022228417A1 (en) 2021-03-01 2023-10-26 Neurocrine Biosciences, Inc. Use of luvadaxistat for the treatment of cognitive impairment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69930624T2 (de) * 1998-06-10 2006-09-14 Meiji Seika Kaisha Ltd. Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie
WO2003047558A2 (en) * 2001-12-03 2003-06-12 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
JO3115B1 (ar) * 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao

Also Published As

Publication number Publication date
EA036438B1 (ru) 2020-11-11
MX2016010524A (es) 2016-10-31
KR20160126081A (ko) 2016-11-01
DK3113778T3 (en) 2018-07-30
PT3113778T (pt) 2018-07-11
IL247435A0 (en) 2016-11-30
CA2940342A1 (en) 2015-09-11
ES2676905T3 (es) 2018-07-26
JP2017507156A (ja) 2017-03-16
JP6510549B2 (ja) 2019-05-08
US20170014407A1 (en) 2017-01-19
UA123352C2 (uk) 2021-03-24
PH12016501751A1 (en) 2017-02-06
ZA201604611B (en) 2017-09-27
EP3113778A1 (en) 2017-01-11
SG11201607106YA (en) 2016-09-29
EA201691566A1 (ru) 2016-12-30
LT3113778T (lt) 2018-08-27
AU2015225954A1 (en) 2016-07-07
GEP20196984B (en) 2019-06-25
TW201534591A (zh) 2015-09-16
CN106102743A (zh) 2016-11-09
WO2015132608A1 (en) 2015-09-11
GB201403944D0 (en) 2014-04-23
MY202127A (en) 2024-04-05
CY1120573T1 (el) 2019-07-10
TR201809537T4 (tr) 2018-07-23
SI3113778T1 (en) 2018-08-31
SMT201800367T1 (it) 2018-09-13
MA39315A1 (fr) 2017-09-29
CL2016002151A1 (es) 2016-12-30
PL3113778T3 (pl) 2018-11-30
EP3113778B1 (en) 2018-06-06
AU2015225954B2 (en) 2020-06-18
RS57594B1 (sr) 2018-11-30

Similar Documents

Publication Publication Date Title
HRP20181082T1 (hr) Derivati piridazina za uporabu za prevenciju ili liječenje ataksičnog poremećaja
JP2017507156A5 (cg-RX-API-DMAC7.html)
HRP20151310T2 (hr) Spojevi piridazinona i njihova uporaba kao inhibitori daao
JP2014524461A5 (cg-RX-API-DMAC7.html)
NZ609955A (en) Sgc stimulators
HRP20180382T1 (hr) Inhibitori protein kinaze
JP2017502049A5 (cg-RX-API-DMAC7.html)
PE20200796A1 (es) Compuestos derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y composiciones que los comprenden
JP2008525498A5 (cg-RX-API-DMAC7.html)
NZ604004A (en) Pyridone and aza-pyridone compounds and methods of use
EA018268B1 (ru) Аналоги пиридона и пиридазона как модуляторы gpr119
HRP20140115T1 (hr) Inhibitori poli(adp-riboza)polimeraza
MY194405A (en) Dihydropyrimidine compounds and uses thereof in medicine
CA2366857A1 (en) Phthalazine derivatives for treating inflammatory diseases
JP2016523935A5 (cg-RX-API-DMAC7.html)
RU2013132930A (ru) Производное пиразола
RU2017120217A (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
IL263511A (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
AR064302A1 (es) Arilpirazoles sustitudos
JP2017500364A5 (cg-RX-API-DMAC7.html)
HRP20241236T1 (hr) Spojevi i pripravci za induciranje hondrogeneze
JP2017523214A5 (cg-RX-API-DMAC7.html)
MX2015017629A (es) Combinaciones farmaceuticas.
RU2016149804A (ru) Производные бензолсульфонамида и их применение в качестве модуляторов орфанного рецептора y, связанного с ретиноевой кислотой
JP2016528274A5 (cg-RX-API-DMAC7.html)